{"id":"NCT05888103","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.","officialTitle":"A 6 Month Randomized, Double-blind, Placebo-controlled Study Followed by a 6 Month Open- Label Extension to Assess the Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-07-11","primaryCompletion":"2024-04-02","completion":"2024-10-24","firstPosted":"2023-06-05","resultsPosted":"2025-04-20","lastUpdate":"2025-04-20"},"enrollment":207,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Primary Hypercholesterolemia or Mixed Dyslipidemia"],"interventions":[{"type":"DRUG","name":"Inclisiran","otherNames":["KJX839"]},{"type":"DRUG","name":"Matching Placebo for Inclisiran","otherNames":["Placebo s.c."]}],"arms":[{"label":"Inclisiran - Inclisiran","type":"EXPERIMENTAL"},{"label":"Placebo- Inclisiran","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the efficacy and safety of inclisiran as a monotherapy in Chinese adults with low or moderate atherosclerotic cardiovascular disease (ASCVD) risk and elevated low-density lipoprotein cholesterol (LDL-C) who were not on any lipid lowering therapy.","primaryOutcome":{"measure":"Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part","timeFrame":"Baseline, Day 150","effectByArm":[{"arm":"Inclisiran - Inclisiran","deltaMin":-45.87,"sd":null},{"arm":"Placebo- Inclisiran","deltaMin":1.62,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":28,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":103},"commonTop":["Upper respiratory tract infection","Blood creatine phosphokinase increased","Blood glucose increased","Alanine aminotransferase increased"]}}